Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00816101 · ClinicalTrials.gov registry record · Phase 2
Efficacy Study of a New Antimicrobial Wound Dressing to Treat Wounds Caused by Curettage and Electrodesiccation
A Phase 2 study of Acute Wounds, sponsored by Vomaris Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT00816101: Completed Phase 2 study of Acute Wounds, sponsored by Vomaris Innovations.
NCT00816101 is a Phase 2 study of Acute Wounds that has completed, run by Vomaris Innovations. The registered enrollment target is 26 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00816101, a Phase 2 study of Acute Wounds, has completed, sponsored by Vomaris Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this pilot clinical study is to compare healing rates, pain levels, and incidence of wound complications including infection with the use of a moist PROCELLERA™ Antimicrobial Wound Dressing when compared to a standard dressing, Mepilex® Border Lite, following curettage and electrodesiccation of skin lesions.
Primary Outcome
Participants were assessed to see whether or not the wound area was reduced by at least 50%, and the number of such participants is reported
Conditions Studied
Interventions
- OTHER Procellera™ Antimicrobial Dressing
- OTHER Mepilex® Border Lite
- DEVICE Adhesive Bandage
Study Locations (1)
Arizona
- Sheftel Associates Dermatology - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
What the finished NCT00816101 record still lists
NCT00816101 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Acute Wounds appearing as the primary indexed condition, and to 3 interventions - of which Procellera™ Antimicrobial Dressing is the first listed.
NCT00816101 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT00816101 about?
NCT00816101 is a clinical study titled "Efficacy Study of a New Antimicrobial Wound Dressing to Treat Wounds Caused by Curettage and Electrodesiccation". The purpose of this pilot clinical study is to compare healing rates, pain levels, and incidence of wound complications including infection with the use of a moist PROCELLERA™ Antimicrobial Wound Dressing when compared to a standard dressing, Mepilex® Border Lite, following curettage and electrodesi...
What is the current status of trial NCT00816101?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2008-03. Estimated completion is 2008-10.
What conditions does trial NCT00816101 study?
This clinical trial studies the following conditions: Acute Wounds.
What interventions are being tested in trial NCT00816101?
The interventions under investigation include: Procellera™ Antimicrobial Dressing (OTHER), Mepilex® Border Lite (OTHER), Adhesive Bandage (DEVICE).
Who is sponsoring clinical trial NCT00816101?
This trial is sponsored by Vomaris Innovations, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00816101 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00816101's enrollment target sits among peer trials
26 1708th of 2000 higher than 282 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia